Immutep Ltd
eftilagimod alfa (efti)
non-small cell lung cancer (1L NSCLC)
Date
TBD
Phase 3 readout · Date TBD estimated
What's at stake
Phase 3 trial results for eftilagimod alfa (efti) in non-small cell lung cancer (1L NSCLC) are due Date TBD. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 6-K
verified 12h ago
“Data from INSIGHT-003 at ESMO Congress 2025 show combination of efti with KEYTRUDA and chemotherapy generates strong response rates across all PD-L1 expression levels in 1L NSCLC, including 61.7% ORR in low & no PD-L1 (TPS <50%), well above”